ArticleJournal of nanobiotechnology2026
Antitumoral activities of λ‑carrageenan oligosaccharide- based nanoparticles.
Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
Polysaccharides (PS) are key building blocks for bioactive nanomaterials in oncology, as they enhance colloidal stability, enable chemical functionalization, support controlled delivery systems, and, for selected families, provide targeting or therapeutic activities. However, despite their high biomedical potential, PS families such as λ-carrageenan (λ-CAR) have remained virtually unexplored in nano-oncology, as poor solubility, restrictive rheological properties, and undesired anticoagulant and pro-inflammatory effects constitute a major barrier to systemic use in vivo. In a recent study, we showed that depolymerized λ-carrageenan oligosaccharides (λ-COS) overcome these limitations and enable the design of stable hybrid nanoparticles embedding free Mn²⁺ ions and ultrasmall ferrite cores (λ-COS NP), exhibiting excellent colloidal stability, in vivo compatibility, and efficient MRI contrast capabilities. Building on this work, the present study investigates the inherent antitumor potential of these "unlocked" λ-COS NP, harnessing the known complementary bioactive properties of the λ-COS scaffold and those of the ferrite/Mn
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.